- Home
- KURA
KURA
Kura Oncology Inc.
as 10-08-2025 12:20pm EST
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 713.5M | IPO Year: | N/A |
| Target Price: | $24.45 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.26 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.41 - $19.73 | Next Earning Date: | 11-06-2025 |
| Revenue: | $83,279,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 68.63% | Revenue Growth (next year): | 141.59% |
Stock Insider Trading Activity of Kura Oncology Inc. (KURA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Bair Teresa Brophy | KURA | Chief Legal Officer | Sep 29 '25 | Sell | $8.94 | 8,805 | $78,736.07 | 148,043 | |
| WILSON TROY EDWARD | KURA | President and CEO | Sep 29 '25 | Sell | $8.94 | 36,615 | $327,418.65 | 246,853 | |
| DOYLE THOMAS JAMES | KURA | SVP, Finance & Accounting | Sep 29 '25 | Sell | $8.94 | 4,541 | $40,606.53 | 109,829 | |
| FORD KATHLEEN | KURA | Chief Operating Officer | Sep 29 '25 | Sell | $8.94 | 6,892 | $61,629.64 | 63,375 | |
| Powl Brian T. | KURA | Chief Commercial Officer | Sep 29 '25 | Sell | $8.94 | 8,891 | $79,505.10 | 99,676 | |
| Leoni Mollie | KURA | Chief Medical Officer | Sep 29 '25 | Sell | $8.94 | 12,314 | $110,114.25 | 158,439 | |
| WILSON TROY EDWARD | KURA | President & CEO | Sep 8 '25 | Buy | $8.20 | 50,000 | $410,145.00 | 100,968 | |
| WILSON TROY EDWARD | KURA | President and CEO | Aug 13 '25 | Buy | $6.64 | 13,494 | $89,623.10 | 100,968 | |
| WILSON TROY EDWARD | KURA | President and CEO | Aug 12 '25 | Buy | $5.85 | 36,506 | $213,578.35 | 100,968 |
Latest Kura Oncology Inc. News
KURA Breaking Stock News: Dive into KURA Ticker-Specific Updates for Smart Investing
GlobeNewswire
14 days ago
Kura Oncology to Participate in Upcoming Investor Conference
Simply Wall St.
18 days ago
Kura Oncology Insider Ups Holding During Year
MT Newswires
22 days ago
Kura Oncology Hosts Event Focused on Farnesyl Transferase Inhibitor Program
GlobeNewswire
22 days ago
Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types
MT Newswires
a month ago
Kura Oncology Insider Bought Shares Worth $410,145, According to a Recent SEC Filing
Insider Monkey
a month ago
LifeSci Capital Maintains Buy Rating on Kura Oncology (KURA)
GlobeNewswire
a month ago
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zacks
4 months ago
Is the Options Market Predicting a Spike in Kura Oncology Stock?
Compare KURA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KURA Kura Oncology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.